Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 35, Issue 9, 2017, Pages 984-993

  Lazarian, Gregory ^a,e   Guièze, Romain ^a,b,d,f   Wu, Catherine J ^a,b,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e AVICENNE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; GENETIC HETEROGENEITY; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMAN; LEUKEMOGENESIS; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TREATMENT RESPONSE; WHOLE EXOME SEQUENCING; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROCEDURES;

GENOMICS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 85016327598     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.0822     Document Type: Review

References (101)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
2. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981
3. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
4. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42, 2013
5. Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014
6. Roberts AW, Davids MS, Pagel JM, et al: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311-322, 2016
7. Garraway LA, Lander ES: Lessons from the cancer genome. Cell 153:17-37, 2013
8. Malek SN: The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 32:2805-2817, 2013
9. Brown JR, Hanna M, Tesar B, et al: Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 18:3791-3802, 2012
10. Ouillette P, Collins R, Shakhan S, et al: Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 118:3051-3061, 2011
11. Edelmann J, Holzmann K, Miller F, et al: Highresolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120:4783-4794, 2012
12. Puente XS, Beà S, Valdés-Mas R, et al: Noncoding recurrent mutations in chronic lymphocytic leukaemia. Nature 526:519-524, 2015
13. Gunnarsson R, Mansouri L, Isaksson A, et al: Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 96:1161-1169, 2011
14. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529, 2002
15. Chapiro E, Leporrier N, Radford-Weiss I, et al: Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res 34:63-68, 2010
16. Pfeifer D, Pantic M, Skatulla I, et al: Genomewide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109:1202-1210, 2007
17. Rubio-Moscardo F, Blesa D, Mestre C, et al: Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106:3214-3222, 2005
18. Puente XS, Pinyol M, Quesada V, et al: Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-105, 2011
19. Wang L, Lawrence MS, Wan Y, et al: SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365:2497-2506, 2011
20. Ramsay AJ, Quesada V, Foronda M, et al: POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 45:526-530, 2013
21. Quesada V, Conde L, Villamor N, et al: Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44:47-52, 2011
22. Rossi D, Fangazio M, Rasi S, et al: Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119:2854-2862, 2012
23. Fabbri G, Rasi S, Rossi D, et al: Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. J Exp Med 208:1389-1401, 2011
24. Landau DA, Carter SL, Stojanov P, et al: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-726, 2013
25. Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219, 2013
26. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-218, 2013
27. Landau DA, Tausch E, Taylor-Weiner AN, et al: Mutations driving CLL and their evolution in progression and relapse. Nature 526:525-530, 2015
28. DeBoever C, Ghia EM, Shepard PJ, et al: Transcriptome sequencing reveals potential mechanism of cryptic 39 splice site selection in SF3B1-mutated cancers. PLOS Comput Biol 11:e1004105, 2015
29. Darman RB, Seiler M, Agrawal AA, et al: Cancer-associated SF3B1 hotspot mutations induce cryptic 39 splice site selection through use of a different branch point. Cell Reports 13:1033-1045, 2015
30. Te Raa GD, Derks IA, Navrkalova V, et al: The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia 29:1133-1142, 2015
31. Wang L, Brooks AN, Fan J, et al: Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell 30:750-763, 2016
32. O'Neil J, Grim J, Strack P, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204:1813-1824, 2007
33. Stilgenbauer S, Schnaiter A, Paschka P, et al: Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial. Blood 123:3247-3254, 2014
34. Austen B, Skowronska A, Baker C, et al: Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 25:5448-5457, 2007
35. Balatti V, Bottoni A, Palamarchuk A, et al: NOTCH1 mutations in CLL associated with trisomy 12. Blood 119:329-331, 2012
36. Riches JC, O'Donovan CJ, Kingdon SJ, et al: Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood 123:4101-4110, 2014
37. Platt RJ, Chen S, Zhou Y, et al: CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440-455, 2014
38. Heckl D, Kowalczyk MS, Yudovich D, et al: Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32:941-946, 2014
39. Wang J, Khiabanian H, Rossi D, et al: Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife 3:e02869, 2014
40. Kulis M, Heath S, Bibikova M, et al: Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 44:1236-1242, 2012
41. Kulis M, Merkel A, Heath S, et al: Wholegenome fingerprint of the DNA methylome during human B cell differentiation. Nat Genet 47:746-756, 2015
42. Oakes CC, Seifert M, Assenov Y, et al: DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 48:253-264, 2016
43. Damm F, Mylonas E, Cosson A, et al: Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4:1088-1101, 2014
44. Kikushige Y, Ishikawa F, Miyamoto T, et al: Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20:246-259, 2011
45. Thompson PA, Tam CS, O'Brien SM, et al: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127:303-309, 2016
46. Fischer K, Bahlo J, Fink AM, et al: Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 127:208-215, 2016
47. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al: Molecular prediction of durable remission after firstline fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 126:1921-1924, 2015
48. Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009
49. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007
50. Robak T, Blonski JZ, Gora-Tybor J, et al: Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108:473-479, 2006
51. Montserrat E, Alcalá A, Parody R, et al: Treatment of chronic lymphocytic leukemia in advanced stages: A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 56:2369-2375, 1985
52. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
53. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001
54. Coiffier B, Lepretre S, Pedersen LM, et al: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 111:1094-1100, 2008
55. Cartron G, de Guibert S, Dilhuydy M-S, et al: Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: Final data from the phase 1/2 GAUGUIN study. Blood 124:2196-2202, 2014
56. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as firstline therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
57. Woyach JA, Furman RR, Liu T-M, et al: Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-2294, 2014
58. Landau DA, Carter SL, Getz G, et al: Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28:34-43, 2014
59. Schuh A, Becq J, Humphray S, et al: Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120:4191-4196, 2012
60. Amin NA, Seymour E, Saiya-Cork K, et al: A quantitative analysis of subclonal and clonal gene mutations before and after therapy in chronic lymphocytic leukemia. Clin Cancer Res 22:4525-4535, 2016
61. Rasi S, Khiabanian H, Ciardullo C, et al: Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. Haematologica 101:e135-e138, 2016
62. Malcikova J, Stano-Kozubik K, Tichy B, et al: Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 29:877-885, 2015
63. Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479, 2010
64. Zenz T, Kröber A, Scherer K, et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term followup. Blood 112:3322-3329, 2008
65. Rossi D, Khiabanian H, Spina V, et al: Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123:2139-2147, 2014
66. Lazarian G, Tausch E, Eclache V, et al: TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer 139:1759-1763, 2016
67. Landau DA, Tausch E, Böttcher S, et al: Quantitative clonal dynamics define mechanisms of CLL evolution in response to combination chemotherapy. Blood 126:362, 2015 (abstr)
68. Guièze R, Robbe P, Clifford R, et al: Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood 126:2110-2117, 2015
69. Cheng S, Guo A, Lu P, et al: Functional characterization of BTK (C481S) mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors. Leukemia 29:895-900, 2015
70. Liu TM, Woyach JA, Zhong Y, et al: Hypermorphic mutation of phospholipase C, g2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood 126:61-68, 2015
71. Burger JA, Landau DA, Taylor-Weiner A, et al: Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 7:11589, 2016
72. Byrd JC, Furman RR, Coutre SE, et al: Threeyear follow-up of treatment-näive and previously treated patients with CLL and SLL receiving singleagent ibrutinib. Blood 125:2497-2506, 2015
73. Winqvist M, Asklid A, Andersson PO, et al: Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program-A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica 101:1573-1580, 2016
74. Thompson PA, O'Brien SM, Wierda WG, et al: Complex karyotype is a stronger predictor than del (17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121:3612-3621, 2015
75. Sutton LA, Ljungström V, Mansouri L, et al: Targeted next-generation sequencing in chronic lymphocytic leukemia: A high-throughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica 100:370-376, 2015
76. Gawad C, Koh W, Quake SR: Single-cell genome sequencing: Current state of the science. Nat Rev Genet 17:175-188, 2016
77. Hughes A E O, Magrini V, Demeter R, et al: Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 10:e1004462, 2014
78. Saadatpour A, Lai S, Guo G, et al: Single-cell analysis in cancer genomics. Trends Genet 31:576-586, 2015
79. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975
80. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
81. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
82. Baliakas P, Hadzidimitriou A, Sutton LA, et al: Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29:329-336, 2015
83. Rossi D, Rasi S, Spina V, et al: Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121:1403-1412, 2013
84. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al: The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 121:468-475, 2013
85. International CLL-IPI Working Group: An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol 17:779-790, 2016
86. Jeromin S, Weissmann S, Haferlach C, et al: SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28:108-117, 2014
87. Mansouri L, Cahill N, Gunnarsson R, et al: NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 27:512-514, 2013
88. Cortese D, Sutton LA, Cahill N, et al: On the way towards a "CLL prognostic index": Focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 28:710-713, 2014
89. Dreger P, Schnaiter A, Zenz T, et al: TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: Six-year follow-up of the GCLLSG CLL3X trial. Blood 121:3284-3288, 2013
90. Rossi D, Rasi S, Fabbri G, et al: Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119:521-529, 2012
91. Pozzo F, Bittolo T, Arruga F, et al: NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia 30:182-189, 2016
92. Austen B, Powell JE, Alvi A, et al: Mutations in the ATM gene lead to impaired overall and treatmentfree survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106:3175-3182, 2005
93. Skowronska A, Parker A, Ahmed G, et al: Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 30:4524-4532, 2012
94. Herling CD, Klaumunzer M, Rocha CK, et al: Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood 128:395-404, 2016
95. Kampjarvi K, Jarvinen TM, Heikkinen T, et al: Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget 6:1884-1888, 2015
96. Parker H, Rose-Zerilli MJ, Larrayoz M, et al: Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia 30:2179-2186, 2016
97. Papaemmanuil E, Gerstung M, Bullinger L, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209-2221, 2016
98. Pospisilova S, Gonzalez D, Malcikova J, et al: ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26:1458-1461, 2012
99. Hallek M: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol 90:446-460, 2015
100. Dreger P, Corradini P, Kimby E, et al: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12-17, 2007
101. Stilgenbauer S, Eichhorst B, Schetelig J, et al: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, openlabel, phase 2 study. Lancet Oncol 17:768-778, 2016